interventional cardiology
Adjust Font Size: Decrease Increase

Micell Technologies® is a cardiovascular company that is enhancing the performance of medical devices with innovative drug-delivery systems. By applying unique surface and polymer modification technologies, Micell can precisely and consistently control drug elution and the duration of bioabsorbable polymer exposure creating the potential for a therapeutic solution for coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Micell is also developing a drug-eluting balloon and a fully absorbable stent for vascular interventions.

The Company's patented processes and methods for medical device surface modification using supercritical fluids are focused on resolving known problems with current durable polymer-based drug-eluting technologies. The company's lead product candidate, MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System ("MiStent® SES") is a CE marked drug-eluting stent designed to merge the therapeutic efficacy potential of a sirolimus-eluting stent with the long-term safety characteristics of a bare-metal stent.

Caution: The MiStent SES has received CE marking but is not approved in the USA or any other countries. Any other products described on this website are investigational devices that are not available for sale in any country.
Home | About Us | Therapeutic Focus | Product Pipeline | Technology | News | Terms of Use | Privacy Policy | Site Map
© 2016 Micell Technologies, Inc. All rights reserved.
"Micell", "MiStent", and "MiStent SES" are registered trademarks of Micell Technologies, Inc.